Endothelial Growth Factors
"Endothelial Growth Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.
| Descriptor ID |
D016228
|
| MeSH Number(s) |
D12.644.276.390 D12.776.467.390 D23.529.390
|
| Concept/Terms |
Endothelial Growth Factors- Endothelial Growth Factors
- Growth Factors, Endothelial
- Endo-GF
- Endothelial Growth Factor Polypeptides
- Endothelial Growth Factor
- Growth Factor, Endothelial
- ECDGF
- Endothelial Cell-Derived Growth Factors
- Endothelial Cell Derived Growth Factors
|
Below are MeSH descriptors whose meaning is more general than "Endothelial Growth Factors".
Below are MeSH descriptors whose meaning is more specific than "Endothelial Growth Factors".
This graph shows the total number of publications written about "Endothelial Growth Factors" by people in this website by year, and whether "Endothelial Growth Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 5 | 3 | 8 |
| 2000 | 3 | 3 | 6 |
| 2001 | 3 | 5 | 8 |
| 2002 | 3 | 4 | 7 |
| 2003 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endothelial Growth Factors" by people in Profiles.
-
Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2023 07 01; 141(7):658-666.
-
Effect of intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration on renal function. Nephrol Dial Transplant. 2023 Jun 30; 38(7):1770-1772.
-
Safety of recent ophthalmic drugs and devices for wet macular degeneration. Curr Opin Ophthalmol. 2023 Sep 01; 34(5):363-368.
-
Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials. Acta Ophthalmol. 2024 Feb; 102(1):e31-e41.
-
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina. 2023 03 01; 43(3):506-513.
-
Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. Eye (Lond). 2023 07; 37(10):1966-1974.
-
Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023 01 20; 41(3):678-700.
-
Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye (Lond). 2023 Jun; 37(9):1928-1935.
-
Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context. BMJ Open Ophthalmol. 2022 08; 7(1).
-
Favorable Anti-VEGF Crunch Syndrome: Nonsurgical Relief of Vitreoretinal Traction in Eyes With Proliferative Diabetic Retinopathy and Tractional Retinal Detachment. Ophthalmic Surg Lasers Imaging Retina. 2022 08; 53(8):455-459.